StreetAlpha.app
Home › Stocks › AMLX

Amylyx Pharmaceuticals, Inc. (AMLX)

Healthcare
$27.52
▼ −1.01%
LAST CLOSE · NOV 17

Amylyx Pharmaceuticals develops drug candidates for endocrine conditions and neurodegenerative diseases, based in Cambridge, Massachusetts. It last closed at $27.52 on Nov 17, down 1.01% on the day. The average 12-month price target from 3 analysts is $45.00 (+63.5% from the last close), with a high of $57.00 and a low of $39.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints totaling $1.9M, the largest $665K.

AI Auto Pilots
Is AMLX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$163.2M
EPS (diluted)
−$1.43
Free cash flow
−$130.0M
Valuation
Market cap
$3.5B
128.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$240.1M
At Sep 30
Shareholder equity
$753.7M
Shares outstanding
128.6M
At Oct 26
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $285K$285KFY2021FY2022: $22.2M$22.2MFY2022FY2023: $380.8M$380.8MFY2023FY2024: $87.4M$87.4MFY2024FY2025: $0$0FY2025

From AMLX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on AMLX in the past 90 days
Average 12-month target
$45.00
▲ 63.5% upside

Based on 3 analysts who set a price target on AMLX in the past 90 days. The average target is $45.00, with a high of $57.00 and a low of $39.00, compared with the last close of $27.52.

Low $39.00Avg $45.00High $57.00
Blue marker: last close $27.52
Highest target$57.00
Average target$45.00
Lowest target$39.00
Latest rating changes
MizuhoTarget lowered
Nov 10Buy$42 → $39
CitigroupTarget raised
Oct 15Buy$26 → $39
GuggenheimTarget raised
Aug 27Buy$55 → $57
MizuhoTarget raised
Aug 19Buy$30 → $42
GuggenheimTarget raised
Aug 19Buy$40 → $55
DateFirmActionRatingPrice target
Nov 10MizuhoTarget loweredBuy$42 → $39
Oct 15CitigroupTarget raisedBuy$26 → $39
Aug 27GuggenheimTarget raisedBuy$55 → $57
Aug 19MizuhoTarget raisedBuy$30 → $42
Aug 19GuggenheimTarget raisedBuy$40 → $55
Loading…

Technical Analysis

AMLX · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 5% below its 20 day and 7% below its 50 day average. It is 24% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 44). The nearest support is the swing low (Nov 5) at $27.48, and the nearest resistance the Pivot R1 at $27.92.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.3%/day
Key levels
$41.1452 week high+49.5%
$29.3950 day average+6.8%
$28.9020 day average+5.0%
$28.60Swing high (Oct 9)+3.9%
$27.92Pivot R1+1.5%
$27.52Last close
$27.48Swing low (Nov 5)−0.1%
$27.26Pivot−0.9%
$26.97100 day average−2.0%
$26.86Pivot S1−2.4%
$20.93200 day average−23.9%
$10.8352 week low−60.6%
Indicators
RSI (14)43.89Middle of its rangeNeutral
MACD0.10Below its signal lineBearish
Stochastic31.0Middle of its rangeNeutral
ADX (14)15.2No clear trend
Williams %R-82.6Oversold below −80, overbought above −20Oversold
CCI (20)-130.8Oversold below −100, overbought above 100Oversold
Rate of change−5.8%Change over 10 sessionsBearish
ATR (14)$1.74Typical daily range, 6.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for AMLX

What happened before

See how AMLX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AMLX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AMLX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AMLX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$1.9M
Largest print
$665K
Loading…

AMLX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲168 buying vs 82 selling
  • ▲Held by funds +13.0 pts
  • ▲Funds holding +23
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding230207+11.1%
In funds' top 10125+140.0%
Held by funds102.9%89.8%+13.0 pts
New / increased59 / 10948 / 71+41.2%
Reduced / sold out45 / 3757 / 13+17.1%
Put/call ratio1.120.48+132.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AMLX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AMLX is in one of them and how their past AMLX trades turned out.

AMLX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AMLX in an article yet. Here's the latest on the wider market.

AMLX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 16
Who traded AMLX · since 2022
Latest 1 filing
$1K – $15KTraded Oct 12, 2022Filed Nov 16, 2022
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYBuy$1K – $15KOct 12, 2022Nov 16, 202235 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals is a drug developer based in Cambridge, Massachusetts. The company is working on treatments for endocrine conditions and neurodegenerative diseases, many of them rare disorders with no approved treatments. Its lead candidate, avexitide, is being studied for a low blood sugar condition that can follow weight loss surgery. Its other programs target Wolfram syndrome, ALS and other rare diseases, with patients as the intended users of these treatments.

Headquarters
Cambridge, MA